Blinded Randomized Trial of Anticoagulation to Prevent Ischemic Stroke and Neurocognitive Impairment in AF
Status:
Recruiting
Trial end date:
2024-02-01
Target enrollment:
Participant gender:
Summary
This is a prospective, multicenter, randomized, double-blinded clinical trial exploring the
efficacy and safety of rivaroxaban as compared to standard of care in reducing stroke,
transient ischemic attack (TIA) and neurocognitive decline, in subjects with non-valvular AF
and with low risk of stroke.
Phase:
Phase 3
Details
Lead Sponsor:
Montreal Heart Institute
Collaborators:
Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma Canadian Institutes of Health Research (CIHR) Canadian Stroke Prevention Intervention Network Hewitt Foundation Montreal Heart Institute Foundation The Montreal Health Innovations Coordinating Center (MHICC)